Steinbjoern H.
- Country
- Denmark
- Department
- Dept of Oncology
Research Overview
- Phase 3 Randomized Double-Blind Trial of Pembrolizumab and Enzalutamide with ADT Versus Placebo and Enzalutamide with ADT in Metastatic Hormone-Sensitive Prostate Cancer
- A Phase 3 Randomized, Open-label Study of Opevesostat Tosylate Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Phase 3 Randomized Double-Blind Study of PF-06821497 and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 26 of 132 partner sites.
Specializations
Prostate Cancer Treatment
This investigator specializes in advanced therapeutic approaches for metastatic prostate cancer, with particular emphasis on treating both castration-resistant and castration-sensitive disease states.
- Advanced-stage prostate cancer management
- Hormone therapy resistance
- Novel therapeutic combinations
The investigator's work encompasses treatment strategies for patients who have progressed after initial hormonal therapy.
Precision Oncology
The research focus includes targeted therapies for patients with specific genetic profiles, particularly those with homologous recombination repair (HRR) gene mutations in prostate cancer.
- Genetic mutation analysis
- Personalized treatment approaches
- Biomarker-driven therapy
The investigator evaluates novel therapeutic combinations specifically designed for genetically defined patient populations.
Treatment Innovation
The investigator explores innovative therapeutic combinations, including hormone therapy alternatives and novel drug combinations for prostate cancer treatment.
- Combination therapy development
- Treatment sequencing strategies
- Clinical outcomes assessment
Research activities focus on comparing established treatments with new therapeutic approaches to improve patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.